City Therapeutics Eyes Valuation of Up to $956.3 Million in US IPO
The City Therapeutics IPO targets a valuation of up to about $956 million at $17 to $19 a share. Terms, RNAi pipeline, financials and risks.
Tag: City Therapeutics IPO
Read More